Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time
Summary Treatment with the direct thrombin inhibitor argatroban (ARG) is often followed by vitamin K-antagonist treatment (VKA). Phenprocoumon (PC) and acenocoumarol (AC) are frequently used in Europe. The standard monitoring test for VKA, prothrombin time (PT), is prolonged by direct thrombin inhib...
Gespeichert in:
Veröffentlicht in: | Thrombosis and haemostasis 2004-06, Vol.91 (6), p.1137-1145 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1145 |
---|---|
container_issue | 6 |
container_start_page | 1137 |
container_title | Thrombosis and haemostasis |
container_volume | 91 |
creator | Harder, Sebastian Graff, Jochen Klinkhardt, Ute von Hentig, Nils Walenga, Jeanine M. Watanabe, Hikari Osakabe, Masanori Breddin, Hans-Klaus |
description | Summary
Treatment with the direct thrombin inhibitor argatroban (ARG) is often followed by vitamin K-antagonist treatment (VKA). Phenprocoumon (PC) and acenocoumarol (AC) are frequently used in Europe. The standard monitoring test for VKA, prothrombin time (PT), is prolonged by direct thrombin inhibitors. Therefore the International Normalized Ratio (INR) obtained during combined treatment does not reflect the true effect of the VKA. A similar interference of the VKA on the activated partial thromboplastin time (aPTT), a monitoring assay for direct thrombin inhibitors, can occur. In 39 healthy volunteers the effect of ARG alone or combined with PC or AC on PT, INR, aPTT, and Ecarin Clotting Time (ECT) was investigated. 6 groups each of 6-8 volunteers received a 5-hour infusion of either 1.0, 2.0 or 3.0 µg/kg/min ARG (days 1, 3, 4 and 5) before initiation of either PC or AC (day 1) and during continued VKA dosing (target INR 2-3). A linear relationship (INR ARG+VKA = intercept + slope * INR
VKA alone
) was observed between the INR measured “on” and “off” ARG.The slope depended on the argatroban dose and on the International Sensitivity Index (ISI) of the PT reagent, the steepest slope (i.e., the largest difference between INR
ARG+VKA
and INR
VKA alone
) was seen with the highest ARG dose and the PT reagent with an ISI of 2.13.There was a close correlation between plasma levels of ARG and aPTT or ECT. Under VKA the ARG-aPTT relationship indicated an increased sensitivity of the aPTT to ARG, VKA treatment had no effect on the prolongation of the ECT induced by argatroban. In conclusion, ARG at doses up to 2 µg/kg/min can be discontinued at an INR of 4.0 on combined therapy with VKA, as this would correspond to an INR between 2.2 and 3.7 for the VKA. If it is necessary to monitor ARG in the critical transition period, the ECT which is not influenced by VKA can be used as an alternative to the aPTT. |
doi_str_mv | 10.1160/TH03-12-0794 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71981971</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71981971</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4584-9968eea2402347d7f7e65bca5823a210cca6ecd6cd48abc250eeba2c80b7bd003</originalsourceid><addsrcrecordid>eNqtkk9v1DAQxSMEoqVw44x8gQsN2M4fJ72hVaFIlbgsEjdr4kw2rhI72E4rvhcfkNnuiiIkbpys8fvpPXmes-yl4O-EqPn77RUvciFzrtryUXYqq1rlddN-e5yd8qLkeS3L6iR7FuMN56Iu2-ppdiIqoaqG89Ps5zaAizZZ79gQ_Mwg7CAF34FjyTMfYGLgkjUedusE99ydTSNbRnRL8MavM135wMCgux8h-OmC4TCgSZGRSFgaybuz5GlnPCc22VtI2LMFQrKUcQD8MkFMD5jr2aWBQBebyScSdmxLyvPsyQBTxBfH8yz7-vFyu7nKr798-rz5cJ2bsmrKvG3rBhFkyWVRql4NCuuqM1A1sgApuDFQo-lr05cNdEZWHLEDaRreqa7nvDjL3hx86QXfV4xJzzYanCZw6NeolWgb0SpB4PkBNMHHGHDQS7C0iB9acL1vSe9b0kLqfUuEvzr6rt2M_QN8rIWA10cAooFpoI6MjX9wTVHJoiDu7YFLo8UZ9Y1fg6ON_CvWHuhoRkgJVgy_LY_7j5RCW9cj4Oxjgv1svEvoEgnBjPYWtY1xRa1Uo2dwazTBLkkXqi51HP2dHtM8UZb5j1lxQUO_5O-84he5wv6w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71981971</pqid></control><display><type>article</type><title>Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time</title><source>Thieme - Connect here FIRST to enable access</source><source>MEDLINE</source><creator>Harder, Sebastian ; Graff, Jochen ; Klinkhardt, Ute ; von Hentig, Nils ; Walenga, Jeanine M. ; Watanabe, Hikari ; Osakabe, Masanori ; Breddin, Hans-Klaus</creator><creatorcontrib>Harder, Sebastian ; Graff, Jochen ; Klinkhardt, Ute ; von Hentig, Nils ; Walenga, Jeanine M. ; Watanabe, Hikari ; Osakabe, Masanori ; Breddin, Hans-Klaus</creatorcontrib><description>Summary
Treatment with the direct thrombin inhibitor argatroban (ARG) is often followed by vitamin K-antagonist treatment (VKA). Phenprocoumon (PC) and acenocoumarol (AC) are frequently used in Europe. The standard monitoring test for VKA, prothrombin time (PT), is prolonged by direct thrombin inhibitors. Therefore the International Normalized Ratio (INR) obtained during combined treatment does not reflect the true effect of the VKA. A similar interference of the VKA on the activated partial thromboplastin time (aPTT), a monitoring assay for direct thrombin inhibitors, can occur. In 39 healthy volunteers the effect of ARG alone or combined with PC or AC on PT, INR, aPTT, and Ecarin Clotting Time (ECT) was investigated. 6 groups each of 6-8 volunteers received a 5-hour infusion of either 1.0, 2.0 or 3.0 µg/kg/min ARG (days 1, 3, 4 and 5) before initiation of either PC or AC (day 1) and during continued VKA dosing (target INR 2-3). A linear relationship (INR ARG+VKA = intercept + slope * INR
VKA alone
) was observed between the INR measured “on” and “off” ARG.The slope depended on the argatroban dose and on the International Sensitivity Index (ISI) of the PT reagent, the steepest slope (i.e., the largest difference between INR
ARG+VKA
and INR
VKA alone
) was seen with the highest ARG dose and the PT reagent with an ISI of 2.13.There was a close correlation between plasma levels of ARG and aPTT or ECT. Under VKA the ARG-aPTT relationship indicated an increased sensitivity of the aPTT to ARG, VKA treatment had no effect on the prolongation of the ECT induced by argatroban. In conclusion, ARG at doses up to 2 µg/kg/min can be discontinued at an INR of 4.0 on combined therapy with VKA, as this would correspond to an INR between 2.2 and 3.7 for the VKA. If it is necessary to monitor ARG in the critical transition period, the ECT which is not influenced by VKA can be used as an alternative to the aPTT.</description><identifier>ISSN: 0340-6245</identifier><identifier>EISSN: 2567-689X</identifier><identifier>DOI: 10.1160/TH03-12-0794</identifier><identifier>PMID: 15175800</identifier><identifier>CODEN: THHADQ</identifier><language>eng</language><publisher>Stuttgart: Schattauer Verlag für Medizin und Naturwissenschaften</publisher><subject>Acenocoumarol - administration & dosage ; Administration, Oral ; Adult ; Anticoagulants - administration & dosage ; Anticoagulants - blood ; Biological and medical sciences ; Blood Coagulation - drug effects ; Blood Coagulation Tests ; Blood Coagulation, Fibrinolysis and Cellular Haemostasis ; Blood coagulation. Blood cells ; Drug Monitoring - methods ; Drug Monitoring - standards ; Drug Therapy, Combination ; Endopeptidases ; Fundamental and applied biological sciences. Psychology ; Hematologic and hematopoietic diseases ; Humans ; International Normalized Ratio ; Male ; Medical sciences ; Molecular and cellular biology ; Partial Thromboplastin Time ; Phenprocoumon - administration & dosage ; Pipecolic Acids - administration & dosage ; Platelet diseases and coagulopathies ; Prothrombin Time ; Regression Analysis ; Statistical Distributions</subject><ispartof>Thrombosis and haemostasis, 2004-06, Vol.91 (6), p.1137-1145</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4584-9968eea2402347d7f7e65bca5823a210cca6ecd6cd48abc250eeba2c80b7bd003</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.thieme-connect.de/products/ejournals/pdf/10.1160/TH03-12-0794.pdf$$EPDF$$P50$$Gthieme$$H</linktopdf><linktohtml>$$Uhttps://www.thieme-connect.de/products/ejournals/html/10.1160/TH03-12-0794$$EHTML$$P50$$Gthieme$$H</linktohtml><link.rule.ids>314,776,780,3004,27903,27904,54537,54538</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15835233$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15175800$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Harder, Sebastian</creatorcontrib><creatorcontrib>Graff, Jochen</creatorcontrib><creatorcontrib>Klinkhardt, Ute</creatorcontrib><creatorcontrib>von Hentig, Nils</creatorcontrib><creatorcontrib>Walenga, Jeanine M.</creatorcontrib><creatorcontrib>Watanabe, Hikari</creatorcontrib><creatorcontrib>Osakabe, Masanori</creatorcontrib><creatorcontrib>Breddin, Hans-Klaus</creatorcontrib><title>Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time</title><title>Thrombosis and haemostasis</title><addtitle>Thromb Haemost</addtitle><description>Summary
Treatment with the direct thrombin inhibitor argatroban (ARG) is often followed by vitamin K-antagonist treatment (VKA). Phenprocoumon (PC) and acenocoumarol (AC) are frequently used in Europe. The standard monitoring test for VKA, prothrombin time (PT), is prolonged by direct thrombin inhibitors. Therefore the International Normalized Ratio (INR) obtained during combined treatment does not reflect the true effect of the VKA. A similar interference of the VKA on the activated partial thromboplastin time (aPTT), a monitoring assay for direct thrombin inhibitors, can occur. In 39 healthy volunteers the effect of ARG alone or combined with PC or AC on PT, INR, aPTT, and Ecarin Clotting Time (ECT) was investigated. 6 groups each of 6-8 volunteers received a 5-hour infusion of either 1.0, 2.0 or 3.0 µg/kg/min ARG (days 1, 3, 4 and 5) before initiation of either PC or AC (day 1) and during continued VKA dosing (target INR 2-3). A linear relationship (INR ARG+VKA = intercept + slope * INR
VKA alone
) was observed between the INR measured “on” and “off” ARG.The slope depended on the argatroban dose and on the International Sensitivity Index (ISI) of the PT reagent, the steepest slope (i.e., the largest difference between INR
ARG+VKA
and INR
VKA alone
) was seen with the highest ARG dose and the PT reagent with an ISI of 2.13.There was a close correlation between plasma levels of ARG and aPTT or ECT. Under VKA the ARG-aPTT relationship indicated an increased sensitivity of the aPTT to ARG, VKA treatment had no effect on the prolongation of the ECT induced by argatroban. In conclusion, ARG at doses up to 2 µg/kg/min can be discontinued at an INR of 4.0 on combined therapy with VKA, as this would correspond to an INR between 2.2 and 3.7 for the VKA. If it is necessary to monitor ARG in the critical transition period, the ECT which is not influenced by VKA can be used as an alternative to the aPTT.</description><subject>Acenocoumarol - administration & dosage</subject><subject>Administration, Oral</subject><subject>Adult</subject><subject>Anticoagulants - administration & dosage</subject><subject>Anticoagulants - blood</subject><subject>Biological and medical sciences</subject><subject>Blood Coagulation - drug effects</subject><subject>Blood Coagulation Tests</subject><subject>Blood Coagulation, Fibrinolysis and Cellular Haemostasis</subject><subject>Blood coagulation. Blood cells</subject><subject>Drug Monitoring - methods</subject><subject>Drug Monitoring - standards</subject><subject>Drug Therapy, Combination</subject><subject>Endopeptidases</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>International Normalized Ratio</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Molecular and cellular biology</subject><subject>Partial Thromboplastin Time</subject><subject>Phenprocoumon - administration & dosage</subject><subject>Pipecolic Acids - administration & dosage</subject><subject>Platelet diseases and coagulopathies</subject><subject>Prothrombin Time</subject><subject>Regression Analysis</subject><subject>Statistical Distributions</subject><issn>0340-6245</issn><issn>2567-689X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqtkk9v1DAQxSMEoqVw44x8gQsN2M4fJ72hVaFIlbgsEjdr4kw2rhI72E4rvhcfkNnuiiIkbpys8fvpPXmes-yl4O-EqPn77RUvciFzrtryUXYqq1rlddN-e5yd8qLkeS3L6iR7FuMN56Iu2-ppdiIqoaqG89Ps5zaAizZZ79gQ_Mwg7CAF34FjyTMfYGLgkjUedusE99ydTSNbRnRL8MavM135wMCgux8h-OmC4TCgSZGRSFgaybuz5GlnPCc22VtI2LMFQrKUcQD8MkFMD5jr2aWBQBebyScSdmxLyvPsyQBTxBfH8yz7-vFyu7nKr798-rz5cJ2bsmrKvG3rBhFkyWVRql4NCuuqM1A1sgApuDFQo-lr05cNdEZWHLEDaRreqa7nvDjL3hx86QXfV4xJzzYanCZw6NeolWgb0SpB4PkBNMHHGHDQS7C0iB9acL1vSe9b0kLqfUuEvzr6rt2M_QN8rIWA10cAooFpoI6MjX9wTVHJoiDu7YFLo8UZ9Y1fg6ON_CvWHuhoRkgJVgy_LY_7j5RCW9cj4Oxjgv1svEvoEgnBjPYWtY1xRa1Uo2dwazTBLkkXqi51HP2dHtM8UZb5j1lxQUO_5O-84he5wv6w</recordid><startdate>200406</startdate><enddate>200406</enddate><creator>Harder, Sebastian</creator><creator>Graff, Jochen</creator><creator>Klinkhardt, Ute</creator><creator>von Hentig, Nils</creator><creator>Walenga, Jeanine M.</creator><creator>Watanabe, Hikari</creator><creator>Osakabe, Masanori</creator><creator>Breddin, Hans-Klaus</creator><general>Schattauer Verlag für Medizin und Naturwissenschaften</general><general>Schattauer GmbH</general><general>Schattauer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200406</creationdate><title>Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time</title><author>Harder, Sebastian ; Graff, Jochen ; Klinkhardt, Ute ; von Hentig, Nils ; Walenga, Jeanine M. ; Watanabe, Hikari ; Osakabe, Masanori ; Breddin, Hans-Klaus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4584-9968eea2402347d7f7e65bca5823a210cca6ecd6cd48abc250eeba2c80b7bd003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Acenocoumarol - administration & dosage</topic><topic>Administration, Oral</topic><topic>Adult</topic><topic>Anticoagulants - administration & dosage</topic><topic>Anticoagulants - blood</topic><topic>Biological and medical sciences</topic><topic>Blood Coagulation - drug effects</topic><topic>Blood Coagulation Tests</topic><topic>Blood Coagulation, Fibrinolysis and Cellular Haemostasis</topic><topic>Blood coagulation. Blood cells</topic><topic>Drug Monitoring - methods</topic><topic>Drug Monitoring - standards</topic><topic>Drug Therapy, Combination</topic><topic>Endopeptidases</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>International Normalized Ratio</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Molecular and cellular biology</topic><topic>Partial Thromboplastin Time</topic><topic>Phenprocoumon - administration & dosage</topic><topic>Pipecolic Acids - administration & dosage</topic><topic>Platelet diseases and coagulopathies</topic><topic>Prothrombin Time</topic><topic>Regression Analysis</topic><topic>Statistical Distributions</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Harder, Sebastian</creatorcontrib><creatorcontrib>Graff, Jochen</creatorcontrib><creatorcontrib>Klinkhardt, Ute</creatorcontrib><creatorcontrib>von Hentig, Nils</creatorcontrib><creatorcontrib>Walenga, Jeanine M.</creatorcontrib><creatorcontrib>Watanabe, Hikari</creatorcontrib><creatorcontrib>Osakabe, Masanori</creatorcontrib><creatorcontrib>Breddin, Hans-Klaus</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Harder, Sebastian</au><au>Graff, Jochen</au><au>Klinkhardt, Ute</au><au>von Hentig, Nils</au><au>Walenga, Jeanine M.</au><au>Watanabe, Hikari</au><au>Osakabe, Masanori</au><au>Breddin, Hans-Klaus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time</atitle><jtitle>Thrombosis and haemostasis</jtitle><addtitle>Thromb Haemost</addtitle><date>2004-06</date><risdate>2004</risdate><volume>91</volume><issue>6</issue><spage>1137</spage><epage>1145</epage><pages>1137-1145</pages><issn>0340-6245</issn><eissn>2567-689X</eissn><coden>THHADQ</coden><abstract>Summary
Treatment with the direct thrombin inhibitor argatroban (ARG) is often followed by vitamin K-antagonist treatment (VKA). Phenprocoumon (PC) and acenocoumarol (AC) are frequently used in Europe. The standard monitoring test for VKA, prothrombin time (PT), is prolonged by direct thrombin inhibitors. Therefore the International Normalized Ratio (INR) obtained during combined treatment does not reflect the true effect of the VKA. A similar interference of the VKA on the activated partial thromboplastin time (aPTT), a monitoring assay for direct thrombin inhibitors, can occur. In 39 healthy volunteers the effect of ARG alone or combined with PC or AC on PT, INR, aPTT, and Ecarin Clotting Time (ECT) was investigated. 6 groups each of 6-8 volunteers received a 5-hour infusion of either 1.0, 2.0 or 3.0 µg/kg/min ARG (days 1, 3, 4 and 5) before initiation of either PC or AC (day 1) and during continued VKA dosing (target INR 2-3). A linear relationship (INR ARG+VKA = intercept + slope * INR
VKA alone
) was observed between the INR measured “on” and “off” ARG.The slope depended on the argatroban dose and on the International Sensitivity Index (ISI) of the PT reagent, the steepest slope (i.e., the largest difference between INR
ARG+VKA
and INR
VKA alone
) was seen with the highest ARG dose and the PT reagent with an ISI of 2.13.There was a close correlation between plasma levels of ARG and aPTT or ECT. Under VKA the ARG-aPTT relationship indicated an increased sensitivity of the aPTT to ARG, VKA treatment had no effect on the prolongation of the ECT induced by argatroban. In conclusion, ARG at doses up to 2 µg/kg/min can be discontinued at an INR of 4.0 on combined therapy with VKA, as this would correspond to an INR between 2.2 and 3.7 for the VKA. If it is necessary to monitor ARG in the critical transition period, the ECT which is not influenced by VKA can be used as an alternative to the aPTT.</abstract><cop>Stuttgart</cop><pub>Schattauer Verlag für Medizin und Naturwissenschaften</pub><pmid>15175800</pmid><doi>10.1160/TH03-12-0794</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0340-6245 |
ispartof | Thrombosis and haemostasis, 2004-06, Vol.91 (6), p.1137-1145 |
issn | 0340-6245 2567-689X |
language | eng |
recordid | cdi_proquest_miscellaneous_71981971 |
source | Thieme - Connect here FIRST to enable access; MEDLINE |
subjects | Acenocoumarol - administration & dosage Administration, Oral Adult Anticoagulants - administration & dosage Anticoagulants - blood Biological and medical sciences Blood Coagulation - drug effects Blood Coagulation Tests Blood Coagulation, Fibrinolysis and Cellular Haemostasis Blood coagulation. Blood cells Drug Monitoring - methods Drug Monitoring - standards Drug Therapy, Combination Endopeptidases Fundamental and applied biological sciences. Psychology Hematologic and hematopoietic diseases Humans International Normalized Ratio Male Medical sciences Molecular and cellular biology Partial Thromboplastin Time Phenprocoumon - administration & dosage Pipecolic Acids - administration & dosage Platelet diseases and coagulopathies Prothrombin Time Regression Analysis Statistical Distributions |
title | Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T21%3A42%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transition%20from%20argatroban%20to%20oral%20anticoagulation%20with%20phenprocoumon%20or%20acenocoumarol:%20effects%20on%20prothrombin%20time,%20activated%20partial%20thromboplastin%20time,%20and%20Ecarin%20Clotting%20Time&rft.jtitle=Thrombosis%20and%20haemostasis&rft.au=Harder,%20Sebastian&rft.date=2004-06&rft.volume=91&rft.issue=6&rft.spage=1137&rft.epage=1145&rft.pages=1137-1145&rft.issn=0340-6245&rft.eissn=2567-689X&rft.coden=THHADQ&rft_id=info:doi/10.1160/TH03-12-0794&rft_dat=%3Cproquest_cross%3E71981971%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71981971&rft_id=info:pmid/15175800&rfr_iscdi=true |